Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27261474 | 1.00 | ALDH1A1 (0.52) | ALDH1A1KDM4EHPGDATMCYP3A4 | |
| SCHEMBL27261471 | 1.00 | ALDH1A1 (0.52) | ALDH1A1KDM4EHPGDATMCYP3A4 | |
| SCHEMBL12354522 | 0.89 | ALDH1A1 (0.50) | ALDH1A1KDM4ECYP3A4CYP2C19GAA | |
| SCHEMBL20833358 | 0.88 | ALDH1A1 (0.50) | ALDH1A1KDM4EHPGDATMCYP3A4 | |
| SCHEMBL23870916 | 0.86 | ALDH1A1 (0.51) | ALDH1A1KDM4EHPGDATMCYP3A4 | |
| SCHEMBL26784888 | 0.86 | ALDH1A1 (0.51) | ALDH1A1KDM4EHPGDATMCYP3A4 | |
| SCHEMBL20343849 | 0.85 | KMT2A (0.44) | ALDH1A1KDM4EHPGDKMT2A | |
| SCHEMBL12363731 | 0.85 | ALDH1A1 (0.56) | ALDH1A1KDM4EHPGDATMGAA | |
| SCHEMBL27261482 | 0.83 | ALDH1A1 (0.44) | ALDH1A1KDM4E | |
| SCHEMBL27261479 | 0.83 | ALDH1A1 (0.44) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054845-A1 | MACROCYCIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054840-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS (US) | 2024-03-14 | — | — | WO | disclosed |
| US-11860540-B2 | Positive resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-01-02 | — | — | US | disclosed |
| EP-2865669-B1 | NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF | SAMJIN PHARM CO LTD (KR) | 2021-04-28 | — | — | EP | disclosed |
| US-10792489-B2 | Bio-electrode composition, bio-electrode, and method for manufacturing the bio-electrode | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-10-06 | — | — | US | disclosed |
| US-10734132-B2 | Bio-electrode composition, bio-electrode, method for manufacturing the bio-electrode, and polymer compound | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-08-04 | — | — | US | disclosed |
| US-10695554-B2 | Bio-electrode composition, bio-electrode, method for manufacturing the bio-electrode, and polymer | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-06-30 | — | — | US | disclosed |
| EP-2297085-B1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20180223133-A1 | BIO-ELECTRODE COMPOSITION, BIO-ELECTRODE, METHOD FOR MANUFACTURING THE BIO-ELECTRODE, AND POLYMER COMPOUND | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2018-08-09 | — | — | US | disclosed |
| US-20180223133-A1 | BIO-ELECTRODE COMPOSITION, BIO-ELECTRODE, METHOD FOR MANUFACTURING THE BIO-ELECTRODE, AND POLYMER COMPOUND | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2018-08-09 | — | — | US | disclosed |
| US-7915212-B2 | Zwitterionic suds stabilizer; cosmetics; extenders for soaps and shampoos; antideposit agents, and antisoilants; terpolymers such as of hydroxyethyl acrylate-dimethylamino/ethyl methacrylate-acrylic acid; depilatories, cleaning compounds, oil well treatment, shaving gels, coagulants | RHODIA INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7629341-B2 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | SYMPHONY EVOLUTION, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| WO-2009146255-A1 | PROSTAGLANDIN PRODUGS AS HYPOTENSIVE AGENTS | ALLERGAN, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009132088-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009117465-A1 | SUBSTITUTED GAMMA LACTAMS AS PROSTAGLANDIN EP2 AGONISTS | ALLERGAN, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009114307-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | VANDERBILT UNIVERSITY | 2009-09-03 | — | — | US | disclosed |
| WO-2009061811-A1 | SUBSTITUTED CYCLOPENTANES HAVING PROSTAGLANDING ACTIVITY | ALLERGAN, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20080131393-A1 | BLOCK POLYMERS, COMPOSITIONS AND METHODS OF USE FOR FOAMS, LAUNDRY DETERGENTS, SHOWER RINSES AND COAGULANTS | RHODIA INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-7335700-B2 | Block polymers, compositions and methods of use for foams, laundry detergents, shower rinses and coagulants | RHODIA INC. (US) | 2008-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080131393-A1 | BLOCK POLYMERS, COMPOSITIONS AND METHODS OF USE FOR FOAMS, LAUNDRY DETERGENTS, SHOWER RINSES AND COAGULANTS | CUTA, GZMB, DAGLB | ALDH1A1 4239/4885KDM4E 380/4885HPGD 3417/4885 |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | ADAM10, ADAM12, ADAM17 | ALDH1A1 4310/4885KDM4E 4160/4885HPGD 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.